Cargando…
Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D
Plasmablastic B-cell malignancies include plasmablastic lymphoma and subsets of multiple myeloma and diffuse large B-cell lymphomaDLBCL. These diseases can be difficult to diagnose and treat, and they lack well-characterized cell line models. Here, immunophenotyping and FOXP1 expression profiling id...
Autores principales: | Gascoyne, Duncan M., Lyne, Linden, Spearman, Hayley, Buffa, Francesca M., Soilleux, Elizabeth J., Banham, Alison H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460784/ https://www.ncbi.nlm.nih.gov/pubmed/28001444 http://dx.doi.org/10.1210/en.2016-1802 |
Ejemplares similares
-
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
por: Wong, Kah Keng, et al.
Publicado: (2016) -
Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma
por: Choi, Qute, et al.
Publicado: (2010) -
The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21(WAF1/CIP1) in 143B Osteosarcoma Cell Growth Arrest
por: Gascoyne, Duncan M., et al.
Publicado: (2015) -
Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder
por: Ramadas, Poornima, et al.
Publicado: (2021) -
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
por: Brown, P J, et al.
Publicado: (2016)